Efficacy and safety of amlodipine/valsartan/hydrochlorothiazide single pill combination in Egyptian patients with hypertension uncontrolled on any dual therapy: an observational study

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics- update: a report from the American Heart Association. Circulation. 2016;133(4):e38–e360.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
   PubMed Web of Science ®Google Scholar
• Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450.
   PubMed Web of Science ®Google Scholar
• GBD Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, –: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–1724.
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Population (Egypt), El-Zanaty and Associates (Egypt), and ICF International. Egypt Health Issues Survey. Cairo (Egypt); Rockville (MD): Ministry of Health and Population and ICF International; 2015.
   Google Scholar
• El Mawardy R, Okba A. Antihypertensive treatment and blood pressure control in patients with hypertension in daily clinical practice: a cross-sectional, multicenter, observational study in Egypt. Curr Med Res Opin. 2017;33(1):39–45.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–2158.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• Milani RV. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy. Am J Manag Care. 2005;11(7 Suppl.):S220–S227.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourcière Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32–39.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Crikelair NA, Yen J, et al. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Adv Ther. 2009;26(11):1012–1023.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourcière Y, Crikelair N, et al. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013;29(8):901–910.
   PubMed Web of Science ®Google Scholar
• Destro M, Crikelair N, Yen J, et al. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag. 2010;6:821–827.
   PubMedGoogle Scholar
• Destro M, Cagnoni F, D'Ospina A, et al. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Vasc Health Risk Manag. 2010;6:253–260.
   PubMedGoogle Scholar
• de la Sierra A, Barrios V. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials. Adv Ther. 2012;29(5):401–415.
   PubMed Web of Science ®Google Scholar
• Doménech M, Coca A. Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure. Patient Prefer Adherence. 2010;4:105–113.
   PubMed Web of Science ®Google Scholar
• Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12:243–249.
   PubMed Web of Science ®Google Scholar
• Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30(12):2415–2422.
   PubMed Web of Science ®Google Scholar
• Khan W, Moin N, Iktidar S, et al. Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. Ther Adv Cardiovasc Dis. 2014;8(2):45–55.
   PubMedGoogle Scholar
• Sison J, Assaad-Khalil SH, Najem R, et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. Curr Med Res Opin. 2014;30(10):1937–1945.
   PubMed Web of Science ®Google Scholar
• Laffer CL, Elijovich F. A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals. Integr Blood Press Control. 2011;4:1–5.
   PubMedGoogle Scholar
• Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013;31(5):251–258.
   PubMed Web of Science ®Google Scholar
• Ragot S, Beneteau M, Guillou-Bonnici F, et al. Prevalence and management of hypertensive patients in clinical practice: cross-sectional registry in five countries outside the European Union. Blood Press. 2016;25(2):104–116.
   PubMed Web of Science ®Google Scholar
• Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011;58(5):745–750.
   PubMed Web of Science ®Google Scholar
• Palatini P, Dorigatti F, Zaetta V, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24(9):1873–1880.
   PubMed Web of Science ®Google Scholar
• Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66(2):133–144.
   PubMed Web of Science ®Google Scholar
• Exforge HCT. Summary of product information. Horsham: Novartis Europharm Limited; 2014.
   Google Scholar
• Reid IA. Angiotensin II and baroreflex control of heart rate. News Physiol Sci. 1996;11:270–274.
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
   PubMed Web of Science ®Google Scholar
• Assaad-Khalil SH, Nashaat N. Real-life effectiveness and safety of amlodipine/valsartan single-pill combination in patients with hypertension in Egypt: results from the EXCITE Study. Drugs Real World Outcomes. 2016;3(3):307–315.
   PubMedGoogle Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147–1152.
   PubMedGoogle Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719.
   PubMed Web of Science ®Google Scholar